SDN-037 Emerging Drug Insight and Market Forecast - 2032

“"SDN-037 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SDN-037 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SDN-037 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SDN-037 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SDN-037 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SDN-037 is a novel long-acting (twice-a-day) formulation of a US FDA-approved ophthalmic steroid for eye pain and inflammation after cataract surgery. Currently marketed steroidal eye drops requires administration every 4-6 h. Apart from providing dosing convenience, SPARC's formulation is clear compared to a marketed formulation which is milky, resulting in blurring of vision after administration.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SDN-037 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on SDN-037 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SDN-037 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around SDN-037.
• The report contains forecasted sales of SDN-037 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for SDN-037 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SDN-037 Analytical Perspective by DelveInsight

In-depth SDN-037 Market Assessment

This report provides a detailed market assessment of SDN-037 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

SDN-037 Clinical Assessment

The report provides the clinical trials information of SDN-037 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SDN-037 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to SDN-037 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SDN-037 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of SDN-037 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SDN-037 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SDN-037?
• What is the clinical trial status of the study related to SDN-037 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SDN-037 development?
• What are the key designations that have been granted to SDN-037 for acute ocular pain?
• What is the forecasted market scenario of SDN-037 for acute ocular pain?
• What are the forecasted sales of SDN-037 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to SDN-037 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?